← Back to headlines
Eli Lilly to Seek FDA Approval for New Weight Loss Drug
Eli Lilly announced plans to seek FDA approval for its next-generation obesity drug in early 2027, following successful results from its latest clinical trials.
23 Jul, 10:45 — 23 Jul, 11:25
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
cnbc
Center
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
cnbcMostly Factual40d ago
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
Read full article →seeking-alphaMixed40d ago
Lilly to seek FDA nod for next-gen weight loss drug early next year after latest trial wins
Read full article →Coverage Timeline
First report: cnbc · 23 Jul, 10:45|Full coverage: 2 · 41m|Window: 41m
Left-leaningCenterRight-leaning
Related Stories
Recent Quarterly GDP Reports Show Growth in Nigeria, Italy, and Lithuania
31m ago
Novo Nordisk Launches Wegovy Weight-Loss Drug in Germany
50m ago
London Stock Exchange Prepares to Launch Tokenized Stock Trading
53m ago
Sasol Reports Improved Second-Half Profits Driven by Operational Upgrades and Debt Reduction
58m ago